<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00731055</url>
  </required_header>
  <id_info>
    <org_study_id>#5649/NIDA-17572-4</org_study_id>
    <secondary_id>R01DA017572</secondary_id>
    <secondary_id>DPMCDA</secondary_id>
    <nct_id>NCT00731055</nct_id>
  </id_info>
  <brief_title>Effects of Varenicline on Cigarette Self Administration</brief_title>
  <official_title>Effects of Varenicline on Cigarette Self Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that varenicline will dose dependently attenuate the subjective
      effects of cigarettes after a period of abstinence. Also, treatment with varenicline will
      dose dependently weaken the severity of nicotine withdrawal symptoms. Thirdly, we hypothesize
      that treatment with varenicline will dose dependently decrease cigarette self-administration
      in the model proposed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tobacco use is the leading preventable cause of death in the U.S.A. Every year 400,000 people
      die from cigarette smoking and in 2006, one out of every five deaths in the US were smoking
      related. Recent advances in laboratory studies of tobacco effects in humans and in
      understanding the effects of nicotine on the brain and behavior present an opportunity to
      advance medication development.

      The addictive properties of nicotine are thought to be a result of nicotine triggering the
      acute release of dopamine, a pleasurable event that a person seeks to repeat. Varenicline is
      a partial agonist of the nicotine receptors, therefore also triggering the release of
      dopamine but in a more sustained and moderate manner, which could counter the low dopamine
      levels arising from a lack of nicotine and therefore aid craving. Also, by binding to these
      nicotine receptors in advance of smoking, it could stop nicotine from binding and creating
      pleasurable effects.

      This study will assess the effect of acute treatment with varenicline and placebo on early
      tobacco withdrawal, acute effects of cigarettes and cigarette self-administration in
      cigarette-smoking volunteers. After overnight abstinence, participants will come into the lab
      and receive acute treatment with varying doses of varenicline or placebo and perform computer
      tests and fill out questionnaires. Then they will be given the opportunity to smoke under
      operational conditions (cigarette versus money choice). This study will employ a
      within-group, double-blind, randomized and counterbalanced design.

      The main goal of this project is to improve the current laboratory model of smoking cessation
      and study the mechanism involved in smoking maintenance. We hypothesize that varenicline will
      dose-dependently: 1) decrease nicotine withdrawal symptoms, 2) decrease acute effects of
      cigarettes and 3) decrease self-administration of cigarettes in the laboratory paradigm.
      Showing the effectiveness of varenicline in the proposed laboratory model will confirm the
      model's predictive validity to detect clinically effective medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cigarette Choice</measure>
    <time_frame>During each of the four weekly 6-hour experimental sessions</time_frame>
    <description>Over each of the four 6-hour experimental sessions, a participant was asked 9 times if they would take money or a cigarette. This outcome measure assesses the number of times a participant chose a cigarette.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Intervention 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant participates in 4 consecutive interventions in random order.
Placebo, 1 capsule before the session
0.5 mg varenicline, 1 capsule before the session 3.1 mg varenicline, 1 capsule before the session
4. 2 mg varenicline, 1 capsule before the session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant participates in 4 consecutive interventions in random order. 1.0.5 mg varenicline, 1 capsule before the session 2. 1 mg varenicline, 1 capsule before the session 3.2 mg varenicline, 1 capsule before the session 4. Placebo, 1 capsule before the session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant participates in 4 consecutive interventions in random order. 1.1 mg varenicline, 1 capsule before the session 2. 2 mg varenicline, 1 capsule before the session 3.Placebo, 1 capsule before the session 4. 0.5 mg varenicline, 1 capsule before the session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant participates in 4 consecutive interventions in random order. 1.2 mg varenicline, 1 capsule before the session 2. Placebo, 1 capsule before the session 3. 0.5 mg varenicline, 1 capsule before the session 4. 1 mg varenicline, 1 capsule before the session</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>4 doses of Varenicline. 1 capsule of either dose (0mg, 0.5mg, 1mg, 2 mg) in the morning on days at least 5 days apart.</description>
    <arm_group_label>Intervention 1</arm_group_label>
    <arm_group_label>Intervention 2</arm_group_label>
    <arm_group_label>Intervention 3</arm_group_label>
    <arm_group_label>Intervention 4</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 dose of placebo</description>
    <arm_group_label>Intervention 1</arm_group_label>
    <arm_group_label>Intervention 2</arm_group_label>
    <arm_group_label>Intervention 3</arm_group_label>
    <arm_group_label>Intervention 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A diagnosis of nicotine dependence with physiological dependence, smoking at least 15
             cigarettes/day during the last 3 months.

          2. Not interested in treatment

          3. Medically healthy on the basis of physical examination and medical history, vital
             signs, EKG and laboratory tests, with a negative pregnancy test for females.

          4. Able to perform study procedures

          5. Males or females between the ages of 21-45 yrs

          6. Female participants agree to use an effective method of birth control during the
             course of the study

        Exclusion Criteria:

          1. A diagnosis of abuse or dependence on alcohol or drugs other than nicotine

          2. Current Axis I diagnosis or current treatment with psychotropic medications (within
             last 3 months)

          3. Lifetime history of schizophrenia or other psychotic disorders, bipolar disorder, or
             anxiety disorders

          4. Currently seeking treatment for nicotine dependence

          5. Participants on parole or probation

          6. History of significant recent violent behavior

          7. Blood pressure &gt; 150/90

          8. History of allergic reaction to any of the study medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Bisaga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2008</study_first_submitted>
  <study_first_submitted_qc>August 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <results_first_submitted>February 19, 2014</results_first_submitted>
  <results_first_submitted_qc>April 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 1, 2015</results_first_posted>
  <last_update_submitted>May 16, 2016</last_update_submitted>
  <last_update_submitted_qc>May 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twenty-one participants were recruited in an urban hospital setting through advertisement in local newspapers and flyers and 16 particiopants were enrolled. Study was conducted at the NYS Psychiatric Institute</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Participants</title>
          <description>This is a within-group study design, all participant who completed the study receive all 4 experimental treatments</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16">This is a within-subjects study design.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Placebo</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Varenicline 0.5 mg</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Varenicline 1.0 mg</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Varenicline 2.0 mg</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Participants</title>
          <description>Each of study participants received one dose of study medication (varenicline 0mg, 0.5mg, 1mg, and 2 mg) before each of the experimental sessions at least 5 days apart.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.5" lower_limit="23" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cigarette Choice</title>
        <description>Over each of the four 6-hour experimental sessions, a participant was asked 9 times if they would take money or a cigarette. This outcome measure assesses the number of times a participant chose a cigarette.</description>
        <time_frame>During each of the four weekly 6-hour experimental sessions</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The outcome of the session during which participant received placebo</description>
          </group>
          <group group_id="O2">
            <title>Varenicline 0.5 mg</title>
            <description>The outcome of the session during which participant received varenicline 0.5 mg</description>
          </group>
          <group group_id="O3">
            <title>Varenicline 1.0 mg</title>
            <description>The outcome of the session during which participant received varenicline 1.0 mg</description>
          </group>
          <group group_id="O4">
            <title>Varenicline 2.0 mg</title>
            <description>The outcome of the session during which participant received varenicline 2.0 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cigarette Choice</title>
          <description>Over each of the four 6-hour experimental sessions, a participant was asked 9 times if they would take money or a cigarette. This outcome measure assesses the number of times a participant chose a cigarette.</description>
          <units>number of cigarette choices (0-9)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="0.51"/>
                    <measurement group_id="O2" value="3.17" spread="0.63"/>
                    <measurement group_id="O3" value="2.83" spread="0.71"/>
                    <measurement group_id="O4" value="2.83" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events reported during 4 experimental sessions</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Participants</title>
          <description>Each of study participants received one dose of study medication (varenicline 0mg, 0.5mg, 1mg, and 2 mg) before each of the experimental sessions at least 5 days apart.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Adam Bisaga</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646-774-6155</phone>
      <email>amb107@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

